Eli Lilly President and CEO Dave Ricks joined the mornings of Maria ‘to discuss his meeting with President Donald Trump, the president who signed an executive order to encourage American drug production and breaking their $ 4.5 billion foundry.
Novo Nordisk, the maker of much -needed drugs Ozempic and Wegovy, said that it will lower thousands of global jobs to simplify the activities and to allocate resources in the direction of diabetes and obesity drugs while rivals take a bite from the market share.
The company announced on Wednesday that it intends to reduce the global workforce by around 9,000 out of 78,400 positions in the company, with around 5,000 cuts in the home of Denmark.
The company provides more money and effort how it sells its diabetes and obesity products and by developing new medicines to focus on those disorders.
Novo Nordisk to sell weight loss for $ 499 in eligible customers
Wegovy injection pennies arranged in Waterbury, Vermont, on April 28, 2025. (Shelby Knowles / Bloomberg via / getty images)
The cutbacks will take place throughout the company, including personnel areas and head office functions. The company will start informing employees in the coming months.
Novo Nordisk announced on Wednesday that it is planning to reduce 9,000 jobs. (Tom Little / File Photo / Reuters -Photos)
Novo Nordisk said that the transformation reflects the company’s dedication to “meet the rising global demand, while also competing in a more dynamic and consumer -controlled obesity market, as evidenced by the recent delay in growth”.
Novo Nordisk lowers Wegovy prices in two for customers who pay money
The company acknowledged that its rapid expansion has created a greater organizational complexity and higher costs in recent years. The job loss is intended to streamline the activities and enable the company to invest further in science, commercial possibilities and production revision, according to Novo Nordisk.
Eli Lilly headquarters in Indianapolis, Indiana, on May 3, 2023. (AJ Mast / Bloomberg via / getty images)
“Our markets evolve, especially in obesity, because it has become competitive and consumer-controlled. Our company must also evolve,” said Novo Nordisk CEO Doustdar, and noted that this means that an elevated performance-based culture is submitted, our resources have ever had effective use of therapy bangings. ”
Eli Lilly’s Zepbound reduces type 2 diabetes risk, research shows
The increase in the competition is largely led by Eli Lilly, who has won aggressive terrain because of the versions of weight loss medicines Zepbound and Mounjaro. Turnover in the second tax quarter grew to $ 10.4 billion, mainly because of both medicines, which have the same active ingredient, tirzepatide, but various approved applications.
Get Fox Business on the Go by clicking here
Novo Nordisk said that it also lost market share because of alternative products made by composing pharmacies that harm its profit.
